NCT03360929View on ClinicalTrials.gov

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

November 13, 2020

Study Completion Date

November 13, 2020

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AZD3759

Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.

Trial Locations (4)

510080

Guangdong General Hospital, Guangzhou

Unknown

0004, Wuhan

0002, Changsha

0003, Hangzhou

All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

LYZZ Alpha Holding Ltd

INDUSTRY

NCT03360929 - Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 | Biotech Hunter | Biotech Hunter